• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-126 作为上皮性卵巢癌预后标志物的临床有效性。

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.

出版信息

Medicine (Baltimore). 2023 Mar 3;102(9):e33085. doi: 10.1097/MD.0000000000033085.

DOI:10.1097/MD.0000000000033085
PMID:36862865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9981431/
Abstract

BACKGROUND

Ovarian cancer is the leading cause of gynecological cancer related death in females worldwide. Our previous study demonstrated that decreased expression of microRNA (miR-126) promoted ovarian cancer angiogenesis and invasion by targeting VEGF-A. This study aimed to evaluate the clinical validity of miR-126 as a prognostic marker for epithelial ovarian cancer (EOC).

PATIENT CONCERNS

The patients with EOC ranged in age from 27 to 79 years, with a mean age of 57 years.

DIAGNOSIS

All patients had never had chemotherapy or biotherapy, and the diagnoses were confirmed pathologically in all cases.

METHODS

MiR-126 levels in EOC tissue and normal ovaries were determined by qRT-PCR. Its prognostic value was analyzed using the Cox proportional hazards regression model. Survival curves were drawn using the Kaplan-Meier method.

RESULTS

In this study, we found that compared to normal tissues, miR-126 expression was lower in EOC tissues, particularly in omental metastases. Though in our previous study we found that miR-126 may inhibit proliferation and invasion in EOC cell lines, but in this study patients with elevated miR-126 expression exhibited poor overall survival and relapse free survival. Multivariate Cox regression analysis showed that miRNA-126 was an independent prognostic factor for poor relapse-free survival (P = .044). Receiver operating characteristic analysis showed that the area under the curve of miR-126 was 0.806 (95% confidence interval, 0.669-0.942).

CONCLUSION

In this study, we established miR-126 as a potential independent biomarker for predicting recurrence in patients with EOC.

摘要

背景

卵巢癌是全球女性妇科癌症相关死亡的主要原因。我们之前的研究表明,miR-126 表达下调通过靶向 VEGF-A 促进卵巢癌血管生成和侵袭。本研究旨在评估 miR-126 作为上皮性卵巢癌(EOC)预后标志物的临床有效性。

患者关注

EOC 患者年龄 27 岁至 79 岁,平均年龄 57 岁。

诊断

所有患者均未接受过化疗或生物治疗,所有病例均经病理证实诊断。

方法

通过 qRT-PCR 测定 EOC 组织和正常卵巢中的 miR-126 水平。使用 Cox 比例风险回归模型分析其预后价值。使用 Kaplan-Meier 方法绘制生存曲线。

结果

在这项研究中,我们发现与正常组织相比,EOC 组织中 miR-126 的表达较低,尤其是在大网膜转移中。尽管在我们之前的研究中发现 miR-126 可能抑制 EOC 细胞系的增殖和侵袭,但在这项研究中,miR-126 表达升高的患者总体生存和无复发生存较差。多变量 Cox 回归分析显示,miRNA-126 是无复发生存不良的独立预后因素(P=0.044)。受试者工作特征分析显示 miR-126 的曲线下面积为 0.806(95%置信区间,0.669-0.942)。

结论

在这项研究中,我们确立了 miR-126 作为预测 EOC 患者复发的潜在独立生物标志物。

相似文献

1
The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer.miR-126 作为上皮性卵巢癌预后标志物的临床有效性。
Medicine (Baltimore). 2023 Mar 3;102(9):e33085. doi: 10.1097/MD.0000000000033085.
2
miR-335 represents an independent prognostic marker in epithelial ovarian cancer.微小RNA-335是上皮性卵巢癌的一个独立预后标志物。
Am J Clin Pathol. 2014 Mar;141(3):437-42. doi: 10.1309/AJCPLYTZGB54ISZC.
3
MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer.微小RNA-25的表达水平是上皮性卵巢癌的一个独立预后因素。
Clin Transl Oncol. 2014 Nov;16(11):954-8. doi: 10.1007/s12094-014-1178-6. Epub 2014 Apr 3.
4
The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.血清miR-199a在上皮性卵巢癌中的诊断、预后及治疗潜力的综合分析及其与临床病理特征的相关性
Tumour Biol. 2016 Aug;37(8):11259-66. doi: 10.1007/s13277-016-4993-2. Epub 2016 Mar 7.
5
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.miR-200c 与 I 期上皮性卵巢癌患者生存的相关性:两个独立肿瘤组织集的回顾性研究。
Lancet Oncol. 2011 Mar;12(3):273-85. doi: 10.1016/S1470-2045(11)70012-2. Epub 2011 Feb 21.
6
Downregulation of miR-1294 associates with prognosis and tumor progression in epithelial ovarian cancer.miR-1294 的下调与上皮性卵巢癌的预后和肿瘤进展相关。
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7646-7652. doi: 10.26355/eurrev_201811_16381.
7
Expression and prognostic significance of microRNA-451 in human epithelial ovarian cancer.微小RNA-451在人上皮性卵巢癌中的表达及预后意义
Eur J Gynaecol Oncol. 2015;36(4):463-8.
8
MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1.微小RNA-150预测上皮性卵巢癌患者预后良好,并通过抑制转录抑制因子ZEB1来抑制细胞侵袭和转移。
PLoS One. 2014 Aug 4;9(8):e103965. doi: 10.1371/journal.pone.0103965. eCollection 2014.
9
MicroRNA-184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation.微小RNA-184作为上皮性卵巢癌潜在的诊断和预后标志物,并调节细胞增殖、凋亡和炎症。
Pharmazie. 2015 Oct;70(10):668-73.
10
High Expression of MicroRNA-200a/b Indicates Potential Diagnostic and Prognostic Biomarkers in Epithelial Ovarian Cancer.高表达的 microRNA-200a/b 可作为上皮性卵巢癌潜在的诊断和预后生物标志物。
Dis Markers. 2022 Mar 25;2022:2751696. doi: 10.1155/2022/2751696. eCollection 2022.

引用本文的文献

1
The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer.微小RNA在卵巢癌预后和诊断中的作用
Int J Mol Sci. 2025 Apr 5;26(7):3413. doi: 10.3390/ijms26073413.
2
Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.多发性骨髓瘤:具有临床潜力的遗传和表观遗传生物标志物
Int J Mol Sci. 2024 Dec 13;25(24):13404. doi: 10.3390/ijms252413404.
3
Integrated miRNA Profiling of Extracellular Vesicles from Uterine Aspirates, Malignant Ascites and Primary-Cultured Ascites Cells for Ovarian Cancer Screening.
用于卵巢癌筛查的子宫抽吸物、恶性腹水及原代培养腹水细胞来源细胞外囊泡的综合miRNA分析
Pharmaceutics. 2024 Jul 5;16(7):902. doi: 10.3390/pharmaceutics16070902.